A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma

Published:2017-03-22 Issue:5 Volume:92 Page:460-466
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Berenson James¹^ORCID,Manges Robert²,Badarinath Suprith³,Cartmell Alan⁴,McIntyre Kristi⁵,Lyons Roger⁶,Harb Wael⁷,Mohamed Hesham⁸,Nourbakhsh Ali⁸,Rifkin Robert⁹

Affiliation:

1. Institute for Myeloma and Bone Cancer ResearchWest Hollywood California

2. Investigative Clinical Research of IndianaIndianapolis Indiana

3. Cancer Specialists of North FloridaJacksonville Florida

4. Comprehensive Blood & Cancer CentersBakersfield California

5. Texas Health Presbyterian Cancer CenterDallas Texas

6. US Oncology Research and Texas OncologySan Antonio Texas

7. Horizon Oncology ResearchLafayette Indiana

8. Bristol‐Myers SquibbPrinceton New Jersey

9. US Oncology Research and Rocky Mountain Cancer CentersDenver Colorado

Funder

Bristol-Myers Squibb

AbbVie

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24687

Reference25 articles.

1. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis

3. Salvage Therapy of Multiple Myeloma: The New Generation Drugs

4. Bristol‐Myers Squibb. Empliciti (elotuzumab) Prescribing Information.http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf

5. Janssen Biotech Inc. Darzalex (daratumumab) Prescribing information.http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036s000lbl.pdf

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy of Multiple Myeloma: Promise and Challenges;ImmunoTargets and Therapy;2021-09

2. Treatment With Elotuzumab in Combination With Dexamethasone Achieves a Complete Remission in a Previously Treated Patient With Multiple Myeloma: A Case Report;Clinical Lymphoma Myeloma and Leukemia;2020-11

3. Approaching the first relapse after autologous transplant in multiple myeloma;ADVANCES IN CELL AND GENE THERAPY;2020-07-20

4. Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials;Journal of Oncology Pharmacy Practice;2020-07-19

5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma;Journal for ImmunoTherapy of Cancer;2020-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3